AlphAIAlphAI — Financial news for AI agents
investing.comSEP 113 min read$PRAX

Top Biotech Picks From Needham & Company for Second Half of 2026

Needham & Company identified five biotech stocks as top picks for the second half of 2026, all with Buy ratings. Key catalysts include clinical data readouts for Praxia Therapeutics (PRAX), Acadia Pharmaceuticals (ACAD), Biogen (BIIB), Axsome Therapeutics (AXSM), and Alkermes (ALKS). Price targets and analyst upgrades were also noted for these companies.

Original reporting
investing.com
Published Sep 11, 2026, 3:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 3:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefSector analysis
Primary signal
$PRAX
Bullish
medium confidence
Mentioned
$PRAX · $ACAD · $BIIB · $AXSM · $ALKS
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PRAXBullishMed
01

Why it matters

Analyst upgrades provide fresh price targets and highlight upcoming clinical milestones, offering traders actionable insight.

02

Market read

The picks focus on companies with imminent Phase 2/3 data, potentially moving biotech equities.

03

What to watch

Valuation may be stretched given the speculative nature of early‑stage trial outcomes.

Relevance 6/10Novelty 6/10Timing: H2 2026 clinical readouts

Background

Needham & Company released its second‑half 2026 biotech pick list, assigning new price targets and Buy ratings.

Company-level read

Ticker impact

$PRAXBullishMedium confidence
Context

Needham maintains a Buy rating and sets a $582 price target for Praxia Therapeutics, citing upcoming Phase 3 EMERALD data readout.

Expected impact

upside if data readout is positive

Evidence & confidence

Analyst upgrade with specific catalyst and price target.

$ACADBullishMedium confidence
Context

Needham assigns a $41 price target to Acadia Pharmaceuticals ahead of Phase 2 RADIANT data readout in September/October.

Expected impact

potential upside on positive trial results

Evidence & confidence

Analyst recommendation tied to near‑term clinical milestone.

$BIIBBullishMedium confidence
Context

Biogen receives a $256 price target from Needham, highlighting multiple Phase 3 readouts through 2029 and a new CRM vendor selection.

Expected impact

moderate upside on continued pipeline success

Evidence & confidence

Analyst upgrade based on long‑term pipeline outlook.

$AXSMBullishMedium confidence
Context

Needham sets a $268 price target for Axsome Therapeutics, noting strong Auvelity sales and upcoming Phase 3 ENGAGE data.

Expected impact

upside if ENGAGE results are favorable

Evidence & confidence

Analyst upgrade with specific sales and trial catalysts.

$ALKSBullishMedium confidence
Context

Needham assigns a $62 price target to Alkermes, citing upcoming orexin franchise data and a recent credit agreement amendment.

Expected impact

potential upside on positive trial readout

Evidence & confidence

Analyst upgrade linked to near‑term clinical and financial developments.

Market effects

Sector

Highlights bullish outlook for biotech sector based on multiple pipeline catalysts.

Regional

U.S. biotech equities may see increased buying pressure.

Global

Potential spillover to global biotech investors tracking U.S. trial data.

Counterpoint

What could challenge this read

If trial readouts miss expectations, the high price targets could lead to sharp corrections.

Key entities

  • Research Firm
    Needham & Company

    Equity research firm issuing the picks.

Read at source← All news

Related articles

OCT 15
$PRAXMed

PRAX Initiated Coverage by UBS -- Price Target Announced at $706

UBS initiated coverage on Praxis Precision Medicine (PRAX) with a 'Buy' rating and a $706 price target. The company's current price is $248.24, which is significantly higher than its GF Value of $11.67, indicating a 2027.2% overvaluation. PRAX has a GF Score of 40, reflecting concerns about its financial health and growth potential. The company is a clinical-stage biopharmaceutical firm focusing on central nervous system disorders.

gurufocus.com2 min
OCT 14
$BIIBMed

52-Week Litifilimab Data in Cutaneous Lupus Erythematosus

Biogen's litifilimab showed continued improvement in CLE patients through week 52, with response rates rising for key metrics. The phase 2 AMETHYST Part A trial randomized 93 adults, with 59 receiving litifilimab. At week 16, 14.7% of litifilimab participants achieved clear or almost clear skin vs. 2.9% with placebo. The drug received FDA Breakthrough Therapy designation for CLE in January 2026. Phase 3 trials are ongoing.

hcplive.com2 min
OCT 13
$ACADMed

ACAD Downgraded by UBS -- Price Target Lowered to $23.00

UBS downgraded Acadia Pharmaceuticals (ACAD) from Buy to Neutral, lowering its price target from $49.00 to $23.00. The company's stock is currently trading at $18.62, with a GF Value™ of $25.90, suggesting it is 28.1% undervalued. Insider sales totaled $1,019,973 over the past three months, and the company has a GF Score™ of 79/100.

gurufocus.com2 min